A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Non-Interventional Study.
- Who it may be relevant to
- Registry conditions: Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer (FAST-GO)
Overview
This study evaluates how the treatment for gastroesophageal cancer affects physical function in patients who receive chemotherapy as part of their treatment for gastroesophageal cancer.
Detailed description
PRIMARY OBJECTIVE:
I. To determine the change in physical function from baseline to 6 months of treatment, as measured by the short physical performance battery (SPPB).
OUTLINE: This is an observational study.
Patients undergo blood sample collection as well as complete surveys, physical function tests and may complete an interview on study.
Interventions
- Other Non-Interventional Study
Non-interventional study
Primary outcome measures
- Change in SPPB [Time frame: Through the end of cancer treatment, an average of 6 months]
Eligibility criteria
Inclusion criteria
- \* Adults ≥ 18 years old at the start of study treatment.
- New diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma.
- Plan to start systemic therapy for resectable or potentially resectable disease.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
- \* Patients with stage I disease with plans to undergo endoscopic resection or surgery alone without perioperative systemic therapy.
- Metastatic disease at the time of diagnosis.
- Patients who are unable to provide informed consent.
- Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
- Currently participating in another intervention research study seeking to improve functional status, alleviate frailty, increase muscle strength, or improve cognitive function.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles
Identifiers
NCT: NCT07517211 · 25-1284 · NCI-2026-00124 · R03AG095803